On January 11, 2024, Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of delinquency from Nasdaq for failing to hold an annual meeting of shareholders within twelve months of the end of its fiscal year on December 31, 2022. This non-compliance with Nasdaq Listing Rule 5620(a) has prompted Nasdaq to require Exicure to submit a plan within 45 days to address how it will regain compliance. Exicure has the opportunity to request an extension of up to 180 days, or until June 28, 2024, to meet the listing requirements. The company has expressed its intention to submit a compliance plan and seek the extension.

On January 11, 2024, Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of delinquency from Nasdaq for failing to hold an annual meeting of shareholders within twelve months of the end of its fiscal year on December 31, 2022. This non-compliance with Nasdaq Listing Rule 5620(a) has prompted Nasdaq to require Exicure to submit a plan within 45 days to address how it will regain compliance. Exicure has the opportunity to request an extension of up to 180 days, or until June 28, 2024, to meet the listing requirements. The company has expressed its intention to submit a compliance plan and seek the extension.